VIVUS, Inc. (VVUS), Arena Pharmaceuticals, Inc. (ARNA) & Some Key Catalysts Approaching

Page 1 of 2

The obesity stocks are perhaps some of the most discussed and followed stocks in the entire biotechnology sector. The two drugs to receive FDA approval so far are Qsymia from VIVUS, Inc. (NASDAQ:VVUS) and Belviq from Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Pharmaceuticals . The third competitor, Orexigen Therapeutics, Inc. (NASDAQ:OREX) is still trying to get the FDA to sign off on their obesity treatment Contrave. The drug is undergoing more tests to determine its cardiovascular effects on a large test group. Once Contrave does get FDA approval, the rally in Orexigen Therapeutics, Inc. (NASDAQ:OREX) can be huge, however investors will also be a little cautious considering the post-approval decline of VIVUS, Inc. (NASDAQ:VVUS) and Arena.

VIVUS, Inc. (NASDAQ:VVUS)

The Decline

Shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) and VIVUS, Inc. (NASDAQ:VVUS) have depreciated significantly since the FDA granted approval to the two treatments. There are three primary reasons behind this post-approval price depreciation. The biggest reason behind any post-approval decline is the profit taking of long term investors. VIVUS, Inc. (NASDAQ:VVUS) has also suffered due to the poor market performance of Qsymia, which has shown slim sales despite huge expectations from the market. The company recently reduced the price of the drug and also introduced a free trial system that could help increase consumer interest. The retention rates of consumers after the trial period have been pretty impressive.

The third reason has been the unexpectedly poor feedback from European regulatory bodies. Investors of both drugs were expecting their products to receive European approval, but any such acceptance is still largely elusive. Despite these issues, investors still believe in these products, and both companies have market capitalizations in excess of $1 billion.

Belviq Launch

Investors have been waiting for a Belviq launch for quite a while now, but DEA scheduling is still elusive. Otherwise Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) is all set to launch Belviq, and the company is partnering up with Esai, which gives this partner a significant share of any future Arena revenues. It is almost 100 days since the DEA application, and the market expects that a decision will be made by the month’s end. On the other hand the European Medical Association (EMA) might give a decision on Belviq during the week’s meeting. If these two approvals come through we will see a mammoth rally in Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)’s stock price.

Pipeline Strength

The key to all biopharmaceutical companies is the strength of their respective pipelines. Even if there are approved candidates available in the market, having a strong pipeline reduces the reliance on a single product and thus reduces the risk for investors. If we compare VIVUS, Inc. (NASDAQ:VVUS) and Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), the latter has the better pipeline.

Page 1 of 2
blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

50 Crazy Facts About Japan You Won’t Believe

Top 10 Least Expensive Hybrid Cars to Save the Planet With

The 10 Biggest ‘Gate’ Controversies in History

The 10 States with the Highest Nursing Shortages Leaving Their Hospitals Depleted

The 10 Best Value Investment Blogs that Every Investor Must Read

The 6 Cheapest Boarding Schools in Europe 2015

The 5 Most Expensive Cars To Insure in the World

The 10 Most Common Genetically Modified Foods

10 Self-Made Billionaires Who Came From Nothing

The 10 Most Expensive Cities to Live in North America

The 13 Most Expensive Headphones in the World to Represent

The Top 20 Wealthiest Soccer Teams in 2014

4 BuzzWorthy Cannabis Stocks And Some Smoking Derivative Plays

The 10 Healthiest Fast Food Chains in America to Dine At

The 5 Most Expensive Cat Food Brands You Can Spoil Your Kitty With

The 6 Best eCommerce Platforms for Small Businesses

The 10 Worst Mistakes an Entrepreneur Can Make

The 5 Most OP Characters in League of Legends to Carry Games and Crush Foes With

The 5 Best Foods to Eat Before Running that Will Help You Pound the Pavement

10 Glaring Plot Holes in The Walking Dead that a Zombie-Filled Bus Could Drive Through

The 5 Biggest Celebrity Stoners Who Love Their Reefer

The 10 Most Overrated Movies Of All Time by Out-of-Touch Critics

Top 6 Least Expensive Cruise Destinations For 2015 that Will Take You to Paradise

10 States with Lowest Substance Abuse Rates in America

The 14 Most Watched TV Finales Ever

The 10 Best Selling Role Playing Games of All Time for PC

10 Most Influential Papers In Economics

Top 8 Biggest Charities in the US

10 Worst Celebrity Career Moves Ever

Top 10 Best Paid Tennis Stars in the World

10 Cities with High Demand for Nurses

6 of the Worst Greeting Card Messages Ever Crafted

How to Make Money in ArcheAge and Build Your Empire

10 Foods To Eat To Lower Cholesterol Levels

The 10 Most Hated Television Characters of All Time

The 30 Worst Halloween Costume Ideas Ever Brought to Horrible Life

10 Vocational Skills in Demand Today with Jobs Waiting to be Filled

10 Best Places to Visit in Central and South America

The 10 Greatest Empires in History Which Nearly Conquered the World

The 6 Cheapest Boarding Schools In America 2015

5 Clear Reasons LoL is Better than DotA, Continues to Rule MOBAs

The Only 9 Teams with a Chance to Win the Super Bowl

The 15 Most Common Phobias in America that Induce Fits of Panic

Top 6 Least Expensive Tourist Destinations in 2014

Jim Goetz, Peter Fenton, Jim Breyer: Top 6 Venture Investors for 2014

Top 15 Billionaires in 2014

5 Pitfalls To Avoid When Buying a Franchise

Top 20 Medical Schools in the US – 2014 Rankings

4 Business Strategies that Turned Jamie Oliver into the World’s Richest Chef

6 Qualities That Make You A Good Team Player

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!